头颈部转移性皮肤附属器癌对芳香化酶抑制剂联合CDK4/6抑制剂持久缓解
本文报告一例48岁绝经后女性,头皮增大病变活检为雌激素和孕激素受体阳性的腺癌,行扩大局部切除加辅助放疗后1.5年出现转移。基于激素受体阳性,给予芳香化酶抑制剂联合CDK4/6抑制剂,获得持久部分缓解达2.5年,患者仍全职工作。作者认为这是首例激素治疗联合CDK4/6抑制剂成功治疗罕见头颈部癌的病例,建议头颈部皮肤腺癌常规行激素受体免疫组化评估。
要点
- 头颈部皮肤腺癌应常规行激素受体免疫组化评估。
- 转移性皮肤附属器癌激素受体阳性者可考虑AI联合CDK4/6抑制剂。
- 本例获得持久部分缓解2.5年,患者仍全职工作。
核心结论
- 激素治疗联合CDK4/6抑制剂对罕见头颈部皮肤附属器癌转移灶可获得持久部分缓解。
研究设计与样本
- 个案报道:一例48岁绝经后女性头皮腺癌,雌激素和孕激素受体阳性,行扩大局部切除加辅助放疗后1.5年出现转移。
主要发现
- 基于肿瘤激素受体谱,给予芳香化酶抑制剂联合CDK4/6抑制剂,获得持久部分缓解达2.5年(截至报告时)。
- 患者继续全职工作。
临床怎么用
- 头颈部皮肤腺癌应常规行激素受体免疫组化评估。
- 激素受体阳性的转移性皮肤附属器癌可考虑芳香化酶抑制剂联合CDK4/6抑制剂治疗。
局限性
- 个案报道,证据级别有限,结论需更多病例验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cutaneous adnexal carcinomas are a very rare group of cancers arising from appendageal structures of the skin. More than half occur in the head and neck region. No standard treatments exist for metastatic disease. METHODS: A 48-year-old postmenopausal female presented with an enlarging scalp lesion. Biopsy showed adenocarcinoma that was positive for estrogen and progesterone receptors. She underwent wide local excision with adjuvant radiation. Unfortunately, she presented with metastatic disease 1.5 years later. RESULTS: Given the tumor's hormone receptor profile, she was started on an aromatase inhibitor (AI) and a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor with a durable partial response for 2.5 years at the time of this report. She continues to work full-time. CONCLUSIONS: This is the first case study describing the success of hormonal therapy combined with a CDK4/6 inhibitor for a rare head and neck cancer. Cutaneous adenocarcinomas in the head and neck region should have routine immunohistochemical assessment of hormone receptors.
引用
- Kapoor N, Narasimman M, Vandergriff T, et al. Metastatic Cutaneous Adnexal Carcinoma of the Head and Neck With Durable Response to an Aromatase Inhibitor Combined With a Cyclin-Dependent Kinase 4/6 Inhibitor. Head Neck. 2026. PMID: 41589608. doi:10.1002/hed.70178
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。